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Abstract
Introduction We evaluated polysomnograms of chronic fatigue
syndrome (CFS) patients with and without fibromyalgia to
determine whether patients in either group had elevated rates of
sleep-disturbed breathing (obstructive sleep apnea or upper
airway resistance syndrome) or periodic leg movement disorder.
We also determined whether feelings of unrefreshing sleep
were associated with differences in sleep architecture from
normal.
Methods We compared sleep structures and subjective scores
on visual analog scales for sleepiness and fatigue in CFS
patients with or without coexisting fibromyalgia (n = 12 and 14,
respectively) with 26 healthy subjects. None had current major
depressive disorder, and all were studied at the same menstrual
phase.
Results CFS patients had significant differences in
polysomnograpic findings from healthy controls and felt sleepier
and more fatigued than controls after a night's sleep. CFS
patients as a group had less total sleep time, lower sleep
efficiency, and less rapid eye movement sleep than controls. A
possible explanation for the unrefreshing quality of sleep in CFS
patients was revealed by stratification of patients into those who
reported more or less sleepiness after a night's sleep (a.m.
sleepier or a.m. less sleepy, respectively). Those in the sleepier
group reported that sleep did not improve their symptoms and
had poorer sleep efficiencies and shorter runs of sleep than both
controls and patients in the less sleepy group; patients in the
less sleepy group reported reduced fatigue and pain after sleep
and had relatively normal sleep structures. This difference in
sleep effects was due primarily to a decrease in the length of
periods of uninterrupted sleep in the a.m. sleepier group.
Conclusion CFS patients had significant differences in
polysomnographic findings from healthy controls and felt
sleepier and more fatigued than controls after a night's sleep.
This difference was due neither to diagnosable sleep disorders
nor to coexisting fibromyalgia but primarily to a decrease in the
length of periods of uninterrupted sleep in the patients with
more sleepiness in the morning than on the night before. This
sleep disruption may explain the overwhelming fatigue, report of
unrefreshing sleep, and pain in this subgroup of patients.
Introduction
Chronic fatigue syndrome (CFS) is a medically unexplained
condition occurring mostly in women and is characterized by
persistent or relapsing fatigue that lasts at least 6 months and
substantially interferes with normal activities. In addition to
severe fatigue, one of the symptoms used for diagnosing CFS
is unrefreshing sleep, and, in fact, this sleep-related problem is
the most common complaint among patients with severe med-
ically unexplained fatigue [1]. An obvious possibility is that
patients with this problem have an underlying sleep disorder or
CES-D = Centers for Epidemiological Study-Depression; CFS = chronic fatigue syndrome; ECG = electrocardiogram; EEG = electroencephalo-
gram; EMG = electromyogram; EOG = electrooculogram; FM = fibromyalgia; PLM = periodic leg movement; PSG = polysomnogram; RDI = respi-
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substantial amounts of interrupted sleep which may be
responsible for the genesis of the illness. This idea was sup-
ported by a recent longitudinal study that indicated that 20%
of a carefully delineated group of CFS patients were found to
have sleep apnea or narcolepsy, exclusions for the diagnosis
of CFS [2].
A number of reports of polysomnography in CFS patients were
remarkable for finding high rates of these sleep disorders plus
periodic leg movement (PLM) disorder [3-5], whereas several
recent studies have found rates to be the same as in controls
[6,7]. One possible reason for this discrepancy is the exist-
ence of coexisting fibromyalgia (FM). None of these previous
papers stratified their patient sample as to the existence of
coexisting FM, and recent data indicate substantial amounts of
sleep-disturbed breathing in patients with this disorder [8,9].
FM is a medically unexplained syndrome characterized by four
quadrant pain and multiple tender points and frequently
occurs in conjunction with CFS [10]. Hence, we evaluated
polysomnograms (PSGs) of CFS patients with and without FM
to determine whether patients in either group had elevated
rates of sleep-disturbed breathing (obstructive sleep apnea or
upper airway resistance syndrome) or PLM disorder.
Another important issue was whether CFS patients would
show abnormalities in their sleep architecture even if clinical
sleep disorders were not present. Two studies have been
done on patients with 'pure' CFS (that is, in patients with nei-
ther sleep disorder nor evidence of current depression,
another illness that can interfere with sleep) with differing
results: one reported low sleep efficiency with increased peri-
ods of wakefulness in CFS [11] and the second found normal
sleep architecture [12]. We decided to extend these studies
and to determine whether the patient's subjective response to
sleep, another source of variability in a clinical sample, might
correlate with or predict sleep disturbance. Therefore, we also
determined whether feelings of unrefreshing sleep were asso-
ciated with differences in sleep architecture from normal.
Materials and methods
Subjects
The subjects were 62 women (32 with CFS and 30 healthy
controls) ranging in age from 27 to 56 years. Subjects older or
younger than those selected were excluded because of age
effects on sleep. There were no differences in age or body
mass index between patients or controls (Table 1). Subjects
were recruited either from our data set of prior research sub-
jects or from the clinical practice of author BHN, who special-
izes in the care of these patients. Other patients were referred
by their physician or were self-referred based on media reports
about our research. All subjects initially completed an exten-
sive health screening form (available at [13]) that over the
years has proven effective in identifying CFS patients (approx-
imately 5% margin of error). This screening vehicle was also
used to exclude patients taking antidepressants, opiates, ster-
oids, hypnotics, and other sedatives, including benzodi-
azepines. Patients screening positive for CFS and controls
indicating their health to be excellent or good – not fair or poor
– arrived at our center, where they gave their informed consent
and were approved by the medical school's institutional review
board to participate in this research (n = 53 patients and 42
healthy controls).
Subsequently, each research subject underwent a complete
medical history and physical examination, including a tender
point evaluation, and a psychiatric diagnostic interview (Quick
Diagnostic Interview Schedule, Q-DIS), all of which were
administered by the study's advanced practice nurse (JF)
under the supervision of BHN. The psychiatric interview [14]
was used to identify DSM-IV (Diagnostic and Statistical Man-
ual of Mental Disorders, Fourth Edition)-based exclusionary
disorders, including schizophrenia, eating disorders, sub-
stance abuse, or bipolar disorder [15], as well as major
depressive disorder, a psychiatric disorder that can disrupt
sleep [16]. Finally, a set of blood tests was done to identify
medical causes of fatigue. These tests included complete
blood count with sedimentation rate, liver and thyroid function
tests, Lyme antibody, anti-nuclear antibodies, rheumatoid fac-
tor, and C-reactive protein.
Following this evaluation, 21 patients and 12 healthy subjects
were dropped from further study for the following reasons:
inadequate criteria for CFS, 3 patients; use of exclusionary
drugs, 6 patients; previously unappreciated medical illness, 1
patient and 2 controls; current depression, 5 patients; obesity,
1 patient; abnormal labs, 1 patient and 5 controls; moved or
no longer interested, 3 patients and 2 controls; and technical
or other problem, 1 patient and 3 controls. The remaining
patients all fulfilled the 1994 case definition for CFS [15]; of
these patients, 14 also fulfilled the American College of Rheu-
matology criteria (1990) for FM [17].
Procedures
Subjects were instructed to refrain from alcohol and caffeine
ingestion and to avoid engaging in prolonged and/or strenu-
ous exercise in the daytime of study nights; thereafter, sub-
jects underwent one night of PSG recording in a quiet, shaded
hospital room. Subjects went to bed at their usual bedtime
(patients: 11:40 p.m. ± 1 hour 9 minutes; controls: 11:15 p.m.
± 1 hour 26 minutes) and slept until 7:15 to 8 a.m. the next
morning.
Measurements
Subjects underwent full nocturnal polysomnography (Compu-
medics, Charlotte, NC, USA) consisting of electroencephalo-
gram (EEG) (C3/A2, O1/A2, and FZ/A2), electrooculogram
(EOG), submental electromyogram (EMG), anterior tibialis
EMG, a lead II electrocardiogram (ECG), thoracic and abdom-
inal motion, airflow using a nasal cannula/pressure transducer
and an oral thermistor, and pulse oximetry. Analog signals forAvailable online http://arthritis-research.com/content/10/3/R56
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EEG, EOG, EMG, ECG, thoracic and abdominal motion, air-
flow, and pulse oximetry were processed on a real-time basis,
using a Dell personal computer (Dell, Round Rock, TX, USA).
Sleep was scored every 30 seconds by a single scorer
according to standard criteria of Rechtschaffen and Kales
[18]. Sleep onset was defined as the first three consecutive
epochs of sleep stage 1 or the first epoch of other stages of
sleep. An arousal was defined according to standard criteria
Table 1
Selected sleep stage variables in healthy controls and chronic fatigue syndrome patients without sleep abnormalities
Healthy Chronic fatigue syndrome
Number 26 26
Age, years 38 ± 8 39 ± 8
Body mass index, kg/m2 24.4 ± 4.8 24.9 ± 5.2
CES-D score 8 ± 7 17 ± 8a
Sleep structure
Time in bed, minutes 453 ± 33 438 ± 42
Total sleep time, minutes 385 ± 39 351 ± 54a
Sleep efficiencyb, percentage 85 ± 8 80 ± 10a
Number of arousals per hour 8.2 ± 5.2 5.7 ± 4.9
Wakefulness, minutes 51 ± 38 61 ± 32
Stage 1, minutes 44 ± 18 33 ± 17a
Wakefulness plus stage 1, minutes 96 ± 43 94 ± 35
Stage 2, minutes 225 ± 36 198 ± 33a
Stage 3, minutes 29 ± 20 46 ± 23a
Stage 4, minutes 5 ± 11 10 ± 15
Slow-wave sleep (stage 3 + 4), minutes 34 ± 26 56 ± 34
Stage REM, minutes 84 ± 25 64 ± 26a
Sleep latencyc, minutes 16 ± 18 26 ± 26
REM latencyd, minutes 105 ± 49 127 ± 65
Median duration of sleep runs, minutes 15.6 ± 18.4 8.9 ± 5.7a
Likert scale (0–15.5)
Sleepiness
Evening 6 ± 4 9 ± 5a
Morning 1 ± 2e 8 ± 4a
Fatigue
Evening 4 ± 4 11 ± 3a
Morning 2 ± 2e 9 ± 4a
Pain
Evening 1 ± 2 7 ± 5a
Morning 0 ± 1 7 ± 5a
Feeling blue
Evening 1 ± 2 2 ± 2
Morning 0 ± 0e 1 ± 3a
Values are presented as mean ± standard deviation. aSignificantly different from healthy controls (P < 0.05, non-paired t test). bTotal sleep time/
time in bed × 100%. cTime from lights out to sleep onset. dTime from lights out to first epoch of stage REM. eSignificantly different from evening (P 
< 0.05, paired t test). CES-D, Centers for Epidemiological Study-Depression; REM, rapid eye movement.Arthritis Research & Therapy    Vol 10 No 3    Togo et al.
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of the American Academy of Sleep Medicine [19] as a return
to alpha- or fast-frequency EEG activity, well differentiated
from the background, lasting at least 3 seconds but no more
than 15 seconds. Respiratory events were defined as any
combination of apnea and hypopnea lasting at least 10 sec-
onds or airflow suggesting flow limitation lasting at least 10
seconds associated with an arousal. Apnea was defined as a
reduction in airflow to less than 10% of waking level in the
nasal cannula and absent airflow in the oral thermistor, and
hypopnea was defined as a decrease in inspiratory airflow to
less than 50% of waking levels. Flow limitation was consid-
ered to occur when there were two or more consecutive
breaths (for an event duration generally greater than or equal
to 10 seconds) that had a flattened or non-sinusoidal appear-
ance but had peak inspiratory amplitudes that did not meet the
greater than 50% reduction requirement of hypopnea. These
events were required to end abruptly with a return to breaths
with sinusoidal shape. The respiratory disturbance index (RDI)
was defined as the total number of apneas, hyponeas, and
flow limitation events per hour of sleep [20]. The RDI including
the flow limitation events terminated by arousal has been pre-
viously shown to be nearly identical to the number of esopha-
geal manometry events terminated by arousal, which have
been called respiratory effort-related arousals [20]. Based on
results by Ayappa and colleagues [20], it was assumed that an
RDI of greater than or equal to 18 events per hour was suffi-
cient to account for excessive daytime sleepiness on the basis
of sleep-disordered breathing, and the diagnosis of sleep-dis-
turbed breathing was then made for patients and healthy con-
trols with this finding. PLMs were defined as four or more
consecutive involuntary leg movements per hour during sleep,
lasting 0.5 to 5.0 seconds, with an intermovement interval of 5
to 90 seconds. Patients were labeled as having Periodic Leg
Movements in Sleep (PLMS) syndrome when the number of
PLMs per hour (index) was greater than 5.
Sleep continuity
Sleep continuity was evaluated by generating a nonparametric
survival curve calculated from the combined data within each
group [21,22] of the varying durations of sequential sleep runs
(that is, continuous epochs of sleep separated from one
another by epochs of wakefulness) and was expressed as the
median duration of all continuous epochs scored as sleep in
each subject. A run of sleep was defined using the sequence
of epoch-based sleep stages represented in the hypnogram.
A run began with a change from waking to any stage of sleep.
A sleep run continued until there was a change from any stage
of sleep to waking. To compare sleep continuity between
groups, all data from all subjects in each group were pooled
and a group survival curve was generated using standard sta-
tistical techniques that take into account the multiple runs of
sleep in each subject [21,22]; this method was derived from
an earlier one [23].
Subjective test
Subjects were asked to indicate their levels of perceived
sleepiness, fatigue, pain, and feeling blue on separate 15.5 cm
visual analog scales (0 to 15.5) given to them immediately
before lights out and after awakening.
Depressed mood
The Centers for Epidemiological Study-Depression (CES-D)
scale was used as an indicator of depressed mood. This 20-
item scale required respondents to rate how often certain
symptoms occurred during the past week on a scale from
rarely or none (0) to most all the time (3). Items were summed
to yield a total score. The higher the value, the more depressed
the mood.
Statistical analyses
We dichotomized patients' data based on their self-reported
sleepiness before and after sleep. We labeled those with more
sleepiness in the morning than on the night before as 'a.m.
sleepier' and those with less sleepiness in the morning than on
the night before as 'a.m. less sleepy'. Changes of sleepiness
before and after sleep as well as changes in the other variables
captured via visual analog scale were assessed using the
paired t test (Tables 1, 2, 3). Differences in measured variables
between groups were assessed using the non-paired t test
(Tables 1 and 2) or analysis of variance (Table 3). Post hoc
analyses used Tukey Student range tests to adjust for multiple
comparisons (Table 3). Interrelationships between subjective
scales/psychological data and sleep structure were tested by
simple Pearson correlation coefficients, and interrelationships
between subjective scales were tested by least squares
regression analyses. A P value of less than 0.05 was consid-
ered statistically significant.
Results
Evaluation of the PSG led us to exclude 10 subjects with clin-
ically significant sleep abnormalities: 3 controls with RDIs of
26, 22.4, and 18/hour, 1 CFS patient with an RDI of 22.1/
hour, 1 CFS/FM patient with an RDI of more than 40/hour, and
1 control, 3 CFS patients, and 1 CFS/FM patient with PLMs.
We included 1 CFS patient and 3 healthy controls with RDIs
of 10.4, 10.8, 10.1, and 9.5/hour, respectively, as these fall
within the range seen in asymptomatic normal subjects in the
study by Ayappa and colleagues [20]. This left a total of 26
CFS patients, 12 with comorbid FM, and 26 healthy control
subjects.
Table 1 depicts the key PSG measures of the healthy controls
and CFS patients. Total sleep time was significantly longer for
healthy controls than patients as were the total durations of
stage 1, stage 2, and rapid eye movement (REM) sleep,
whereas total duration of wakefulness did not differ between
healthy controls and patients. As a result, patients had a signif-
icantly lower sleep efficiency (that is, the percentage of the
total time asleep after falling asleep relative to the time spentAvailable online http://arthritis-research.com/content/10/3/R56
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in bed) than healthy controls. However, sleep latency, defined
as the time from lights out to the first three consecutive epochs
of sleep stage 1 or the first epoch of other stages of sleep (that
is, sleep onset), and total duration of slow-wave sleep (SWS)
(that is, the sum of stage 3 and 4 sleep) did not differ signifi-
cantly between groups. Data were also evaluated based on
whether the patient had CFS alone or CFS plus FM (Table 2).
Patients with CFS plus FM had sleep structures similar to
those of patients with CFS alone.
Table 1 also shows that sleepiness, fatigue, and pain before
and after the PSG night were significantly higher in patients
than healthy controls. Values for subjective a.m. sleepiness,
fatigue, and feeling blue decreased compared with the
evening in healthy controls, whereas none of these decreased
for patients.
For patients, self-rated sleepiness, fatigue, and pain before
sleep correlated positively with sleep efficiency (r = 0.39,
0.59, 0.57; P < 0.05) and duration of stage 4 sleep (r = 0.48,
0.42, 0.56; P < 0.05) and negatively with sleep latency (r = -
0.40, -0.42, -0.40; P < 0.05); self-rated fatigue and pain cor-
related negatively with durations of wakefulness after sleep
onset (r = -0.50, -0.43; P < 0.05) and wakefulness plus stage
1 sleep (r = -0.50, -0.57; P < 0.05). Self-rated fatigue corre-
lated negatively with REM latency (r = -0.49; P < 0.05). Self-
rated pain correlated positively with total sleep time (r = 0.49;
P < 0.05) and durations of stage 3 sleep (r = 0.49; P < 0.05)
and SWS (r = 0.59; P < 0.05). Moreover, change in self-rated
sleepiness and fatigue over the night correlated positively with
sleep latency (r = 0.39, 0.49; P < 0.05) and negatively with
sleep efficiency (r = -0.41, -0.54; P < 0.05). Changes in self-
rated fatigue over the night correlated negatively with total
sleep time (r = -0.39; P < 0.05) and total duration of stage 3
sleep (r = -0.41; P < 0.05). No significant relations were found
among any of these variables for the healthy control group.
When we looked at correlations between self-rated variables
reported after sleep and sleep stage variables, none was sig-
nificant except that self-rated sleepiness after sleep correlated
positively with duration of stage 2 sleep (r = 0.48; P < 0.05)
for the healthy controls.
Patients in the a.m. sleepier group showed significantly longer
sleep latency, poorer sleep efficiency, and shorter duration of
median sleep run than healthy controls (Table 3). The survival
curve of all sleep runs depicted in Figure 1 shows that patients
in the a.m. sleepier group had a lower percentage of long runs
of sleep than the other two groups and healthy controls (that
is, less continuous sleep). For example, the proportions of runs
lasting more than 10 minutes were 39.3%, 45.5%, and 49.0%
for patients in the a.m. sleepier group, the a.m. less sleepy
group, and healthy controls, respectively. The difference in
temporal distribution of periods of wakefulness is evident from
the representative data in Figure 1. Both the control subject
and the a.m. less sleepy patient have periods of wakefulness
that are spaced more evenly over time than is the case for the
a.m. sleepier patient, whose periods of wakefulness appear
bunched in time (Figure 1a). The frequencies of these bouts
Table 2
Selected sleep stage variables in chronic fatigue syndrome 
patients with and without coexisting fibromyalgia
CFS alone CFS + FM
Number 14 12
Age, years 37 ± 9 41 ± 6
Body mass index, kg/m2 23.3 ± 5.0 26.7 ± 6.0
CES-D score 17 ± 7 18 ± 10
Sleep structure
Time in bed, minutes 440 ± 40 436 ± 46
Total sleep time, minutes 346 ± 60 358 ± 49
Sleep efficiency, percentage 78 ± 10 82 ± 9
Number of arousals per hour 6.2 ± 6.2 5.2 ± 3.2
Wakefulness, minutes 63 ± 27 59 ± 39
Stage 1, minutes 38 ± 20 27 ± 10
Wakefulness plus stage 1, minutes 101 ± 28 86 ± 41
Stage 2, minutes 203 ± 35 192 ± 30
Stage 3, minutes 35 ± 23 59 ± 16
Stage 4, minutes 10 ± 16 11 ± 15
Slow-wave sleep (stage 3 + 4), minutes 45 ± 34 70 ± 28
Stage REM, minutes 60 ± 22 69 ± 30
Sleep latency, minutes 31 ± 27 20 ± 24
REM latency, minutes 149 ± 77 101 ± 37
Median duration of sleep runs, minutes 8.5 ± 5.9 9.5 ± 5.5
Likert scale (0–15.5)
Sleepiness
Evening 10 ± 5 8 ± 3
Morning 9 ± 4 7 ± 3
Fatigue
Evening 10 ± 3 11 ± 3
Morning 9 ± 4 10 ± 3
Pain
Evening 6 ± 6 9 ± 3
Morning 6 ± 5 9 ± 4
Feeling blue
Evening 1 ± 1 2 ± 3
Morning 1 ± 3 1 ± 2
Values are presented as mean ± standard deviation. CES-D, Centers 
for Epidemiological Study-Depression; CFS, chronic fatigue 
syndrome; FM, fibromyalgia; REM, rapid eye movement.Arthritis Research & Therapy    Vol 10 No 3    Togo et al.
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Table 3
Selected sleep stage variables in healthy controls and chronic fatigue syndrome patients who were either less sleepy or sleepier 
after polysomnography
Healthy CFS a.m. less sleepya CFS a.m. sleepiera
Number 26 14 12
Age, years 37 ± 8 39 ± 8 39 ± 8
Body mass index, kg/m2 24.0 ± 4.4 24.1 ± 5.7 25.8 ± 4.7
CES-D score 8 ± 7 20 ± 8b 14 ± 7b,c
Sleep structure
Time in bed, minutes 453 ± 33 433 ± 41 445 ± 44
Total sleep time, minutes 385 ± 38 350 ± 50b 353 ± 61b
Sleep efficiency, percentage 85 ± 8 81 ± 9 79 ± 10b
Number of arousals per hour 8.3 ± 5.2 4.8 ± 3.7 6.7 ± 6.1
Wakefulness, minutes 52 ± 38 64 ± 33 61 ± 35
Stage 1, minutes 45 ± 19 32 ± 12 34 ± 22
Wakefulness plus stage 1, minutes 96 ± 44 96 ± 34 95 ± 37
Stage 2, minutes 222 ± 34 195 ± 29b 202 ± 38
Stage 3, minutes 30 ± 22 50 ± 20b 41 ± 26
Stage 4, minutes 5 ± 11 13 ± 15 7 ± 15
Slow-wave sleep (stage 3 + 4), minutes 35 ± 26 63 ± 30b 48 ± 37
Stage REM, minutes 83 ± 24 60 ± 18b 69 ± 33
Sleep latency, minutes 16 ± 19 20 ± 20 32 ± 31b
REM latency, minutes 107 ± 49 128 ± 64 126 ± 69
Median duration of sleep runs, minutes 15.6 ± 18.4 10.0 ± 6.7 7.9 ± 3.3b
Likert scale (0–15.5)
Sleepiness
Evening 6 ± 4 12 ± 2b 6 ± 5c
Morning 1 ± 2d 7 ± 4b,d 10 ± 2b-d
Fatigue
Evening 4 ± 4 11 ± 3b 10 ± 3b
Morning 1 ± 2d 8 ± 4b,d 11 ± 3b,c
Pain
Evening 1 ± 2 8 ± 4b 7 ± 5b
Morning 0 ± 1 6 ± 4b,d 9 ± 4b,c
Feeling blue
Evening 1 ± 2 2 ± 3 1 ± 1
Morning 0 ± 0d 1 ± 3 1 ± 3
Values are presented as mean ± standard deviation. aData dichotomized based on difference between daytime and nighttime self-reported ratings 
of sleepiness (P < 0.05, analysis of variance [ANOVA]). bSignificantly different from healthy controls. cSignificantly different from CFS in the a.m. 
less sleepy group (P < 0.05, ANOVA). dSignificantly different from evening (P < 0.05, paired t test). CES-D, Centers for Epidemiological Study-
Depression; CFS, chronic fatigue syndrome; REM, rapid eye movement.Available online http://arthritis-research.com/content/10/3/R56
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occurring after sleep onset did not differ among groups (25 ±
15, 21 ± 5, and 23 ± 7 for patients in the a.m. sleepier group,
in the a.m. less sleepy group, and for healthy controls,
respectively).
The existence of coexisting FM did not predict sleep quality for
patients (n = 7 in the a.m. less sleepy group and 5 in the a.m.
sleepier group). Patients in the a.m. less sleepy group had sig-
nificantly higher CES-D scores than those in the a.m. sleepier
group (Table 3).
Prior to going to sleep, the a.m. less sleepy patient group
reported more sleepiness than both healthy controls and
patients in the a.m. sleepier group (P < 0.05). On the morning
after their night in the sleep lab, patients in the a.m. sleepier
group had significantly more sleepiness, fatigue, and pain than
both healthy controls and patients in the a.m. less sleepy
group (P < 0.05). Whereas fatigue and pain did decrease for
patients in the a.m. less sleepy group, neither of these symp-
toms changed for patients in the a.m. sleepier group (Table 3).
Visual analog scores for feeling blue showed minor differences
among groups with little change after the night in the sleep lab
(Table 3). Sleepiness and fatigue in both evening and morning
Figure 1
Sleep-wake patterns and survival curves for the duration of every episode of sleep Sleep-wake patterns and survival curves for the duration of every episode of sleep. (a) Representative sleep-wake patterns from one healthy control, 
one patient in the a.m. less sleepy group, and one patient in the a.m. sleepier group. In contrast to the control and a.m. less sleepy patient, the a.m. 
sleepier patient shows clustering of her arousals, which is documented in the accompanying panel. (b) Survival curves of every episode of sleep 
(that is, a bout of sleep preceded and followed by periods of wakefulness) for controls and patients in the a.m. less sleepy and a.m. sleepier groups 
for whole-night hypnograms stratified by the duration of the sleep episode. To compare sleep continuity between groups, all data from all subjects in 
each group were pooled and a group survival curve was generated using standard statistical techniques [22]. Patients in the a.m. sleepier group 
showed a significant shift toward shorter bouts of sleep (P < 0.05) compared with the other groups. CFS, chronic fatigue syndrome.Arthritis Research & Therapy    Vol 10 No 3    Togo et al.
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were correlated (P < 0.05) in both patients and controls. Sig-
nificant correlations were found for pain and fatigue reported
in the evening and morning for patients but only in the evening
for controls.
Discussion
CFS is diagnosed using clinical criteria and is therefore prob-
ably comprised of a heterogeneous patient pool. The data
reported here indicate that some CFS patients have a problem
with normal regenerative sleep, which may be responsible for
the genesis of their symptoms. In this study, we reduced
patient pool heterogeneity by studying women only during a
fixed period of their menstrual cycle and after excluding
patients with either major depressive disorder or PSG-defined
sleep disorders. As a group, the patients studied showed evi-
dence for sleep disruption in the form of significantly reduced
total sleep time, reduced sleep efficiency, and shorter bouts of
sleep than healthy controls. In comparison with controls, sleep
in CFS had little effect on either self-reported sleepiness or
fatigue. And, interestingly, for patients only, ratings of sleepi-
ness and fatigue correlated well with total sleep duration and
efficiency.
Stratifying patients as to the presence of comorbid FM did not
further reduce the heterogeneity seen in the patients' sleep
structure. However, asking them about their level of sleepiness
before they went to sleep and immediately after awakening
did. Dichotomizing the patients into a group that felt sleepier
after a night's sleep than before sleep and a group that felt less
sleepy after a night's sleep reduced the variability of the sleep
records considerably. Those patients reporting less sleepi-
ness after a night's sleep had sleep structures similar to those
for healthy controls except for a shorter total sleep time and a
commensurate reduction in stage 2 sleep; moreover, they
reported their fatigue and pain to diminish following sleep. In
contrast, patients in the a.m. sleepier group had the greatest
abnormalities of sleep architecture, including poor sleep effi-
ciency, longer sleep latency, and more disrupted sleep as
manifested by a higher percentage of short-duration sleep
runs, than either controls or patients in the a.m. less sleepy
group (Figure 1).
The net effect of this sleep disruption may be the genesis of
symptoms reported by this group of CFS patients. The effects
of sleep disruption are well known to produce severe daytime
fatigue, an example being patients with sleep apnea who have
very disturbed sleep. In the case of CFS, neither arousals nor
periods of wakefulness per se may be the problem so much as
the pattern in which they occur. Patients in the a.m. sleepier
group had a shift away from longer bouts of sleep to more fre-
quent short-sleep bouts (that is, fragmented sleep, which may
prevent them from falling back to sleep after awakening),
resulting in their developing fatigue, unrefreshing sleep, cogni-
tive problems, and achiness. These data appear to support the
sleep continuity theory, which hypothesizes that good sleep
quality requires longer periods of uninterrupted sleep [24].
Reduced energy and cognitive problems are known to occur
in healthy controls who have normal sleep time despite dis-
rupted sleep produced experimentally [25]. In addition, some
studies in healthy volunteers have reported increases in mus-
culoskeletal pain and/or decreases in pain threshold after a
period of sleep disruption or deprivation [26-28]. We are cur-
rently testing the hypothesis that the process responsible for
disturbing the sleep of this group of CFS patients is an imbal-
ance of the cytokine sleep network (that is, sleep-producing
and sleep-disrupting cytokines) in favor of sleep-disrupting
cytokines.
One purpose of this study was to determine whether stratify-
ing our patient sample into those with and without comorbid
FM would explain discrepancies in the literature as to rates of
sleep pathology. It did not. Regardless of the presence of FM,
our findings were similar to earlier reports of rather low rates
of sleep pathology in CFS [6,7]. The low rates of sleep-dis-
turbed breathing and PLMs we found in both patient groups
are similar to those we found in our control group of sedentary
women – rates that approached the values reported in the lit-
erature for unselected populations of healthy women [29,30].
However, in our hands, we found low rates of sleep-disturbed
breathing for patients with CFS alone or CFS plus FM.
Importantly, the rates we found for sleep disturbed breathing
include data along the entire spectrum of sleep disturbed
breathing from overt sleep apnea to the upper airway resist-
ance syndrome. The monitoring technique we used for airflow,
a nasal cannula and examination of the flow signal for the char-
acteristic shape of flow limitation, should have detected subtle
forms of sleep disturbed breathing in our sleep studies, but
only rare occurrences of patterns of air flow consistent with
flow limitation were found here. Thus, although we did not use
the more invasive technique of esophageal manometry to
detect respiratory effort-related arousals, our results do not
support an association between subtle forms of sleep dis-
turbed breathing and CFS, even when co-morbid FM is
present. This conclusion contrasts with an earlier report of
EEG patterns "related to subtle, undiagnosed sleep-disor-
dered breathing" in patients with chronic fatigue [31]. The
apparent difference between these studies may relate to diag-
nostic specificity for CFS. All of our patients fulfilled the 1994
case definition for CFS, which requires their having disabling
fatigue for at least 6 months plus at least four of eight infec-
tious, neuropsychiatric, or rheumatological symptoms [15];
the subjects in the earlier study just had fatigue of long dura-
tion. Thus, our study does not eliminate the possibility that
some patients with severe fatigue alone may have this problem
as a result of subtle forms of sleep-disturbed breathing.
In summary, based on sleep patterns as assessed by polysom-
nography, patients with CFS alone and CFS plus FM have a
similar rate of diagnosable sleep disorders; in fact, neitherAvailable online http://arthritis-research.com/content/10/3/R56
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group has rates of sleep disorders higher than those found in
healthy controls. Thus, sleep-disturbed breathing, narcolepsy,
and leg movement disorders are an uncommon cause of med-
ically unexplained fatigue or pain syndromes. Moreover, after
excluding those patients from further analysis, CFS and FM
patients have similar sleep structures. Our results also sug-
gest that, even when the rate of arousals is within the normal
range, sleep quality may be affected by a decrease in the
length of episodes of uninterrupted sleep.
Conclusion
CFS patients had significant differences in polysomnograpic
findings from healthy controls and felt sleepier and more
fatigued than controls after a night's sleep. This difference was
due neither to diagnosable sleep disorders nor to coexisting
FM but primarily to a decrease in the length of periods of unin-
terrupted sleep in the patients with more sleepiness in the
morning than on the night before. This sleep disruption may
explain the overwhelming fatigue, report of unrefreshing sleep,
and pain of patients in this subgroup.
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